Insmed Provides Business Update and Financial Outlook for 2024

Details

Morgan Healthcare Conference. Full-year 2023 ARIKAYCE revenues are expected to be approximately $305.2 million, with anticipated 2024 revenues between $340 million and $360 million. Topline data from the Phase 3 ASPEN study of Brensocatib in bronchiectasis patients is expected in the latter part of Q2 2024, while enrollment in the Phase 2 study of TPIP in PH-ILD patients is complete with data expected in Q2 2024. Insmed also anticipates launching Brensocatib in the U.S. in mid-2025, followed by Europe and Japan in H1 2026.

Items reported

Exhibits (2)

About Insmed Inc.

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.